Abstracts | 83 included) and Mantel Haenszel-Risk Ratio of 1.31, 95% CI=1.01 to 1.69 (p=0.04) favouring active treatment over placebo according to response rates (12 studies included). Trials were patients merely had BLT as active treatment indicated a higher effect size (Hedges`s g= -0.51, 95%CI =-0.70 to -0.32 and p=0.001) than studies with concomitant psychopharmacological treatment (Hedges`s g= -0.18, 95% CI= -0.41 to 0.06, p=0.15). Conclusion: According to our findings, bright light therapy can be regarded as an effective treatment in seasonal affective disorder compared with placebo conditions. Key words: light therapy, phototherapy, meta-analysis, seasonal affective disorder Method: Current diagnostic characteristics were evaluated using the Structured Clinical Interview for DSM-IV. The CUDOS was measured and compared with three clinician rating scales and four self-report scales. Reliability and validity tests and receiver operating characteristic curve analysis were performed, and the ability to discriminate between levels of severity and the sensitivity to change after treatment were explored. Results: In total, 891 new psychiatric outpatients (58% women) were analyzed. The most frequent DSM-IV diagnoses was MDD (41%). The CUDOS showed excellent results for internal consistency, test-retest reliability, and convergent and discriminant validity. The CUDOS had a high ability to discriminate between different levels of depression severity, and was sensitive to change after treatment. In major depression the area under curve were 0.867. The scores of 20 (sensitivity: 89.9%, specificity: 69.5%) as the optimal cutoff point were suggested when screening for major depression using the CUDOS. Limitation: Subjects are restricted to clinical outpatients. This sample may not fully representative of community-dwelling populations.
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Subthreshold depression persists and increases the risk for depression in late adolescence: a one-year cohort study. The aims of this study were to identify (1) whether first-year university students' subthreshold depressive symptoms persisted for one year, and (2) whether the subthreshold depressive students transitioned to MDE over one year. Therefore, we conducted a cohort study of first-year university students throughout their first year to examine the course of their depressive symptoms. Methods: Participants were divided into three groups by the Beck Depression Inventory (2nd edition; BDI-II) scores of annual checkup (Group 1: BDI-II score ≦ 10, Group 2: BDI-II score = 11-17, and Group 3: BDI-II score ≧18). This inventory was administered every two months. We also administered the Composite International Diagnostic Interview (CIDI) and self-reported instruments at baseline and one year later. Data were analyzed with analysis of variance (ANOVA), chi-square tests, linear mixed modeling, Fisher's exact test, and growth mixture modeling. Results: Subthreshold depression persisted throughout the year in all three groups, but was significantly different between groups throughout the year. Three students from Group 3 developed a new major depressive episode during the year. We conducted growth mixture modeling to identify subtypes of longitudinal trajectories of depressive symptoms. The results reported three classes: there was no significant change in depressive symptoms in class 1 (n = 65). Class 2 (n = 81) demonstrated a significant decrease in depressive symptoms (p < .01) and class 3 (n = 26) revealed a significant increase (p < .05). Class 3 included 4 participants from Group 2 and 24 participants from Group 3. Conclusions: Subthreshold depressive symptoms remained throughout the year and participants who had BDI-II scores greater than or equal to 15 at baseline assessment may be at greater risk and in need of treatment. These findings indicate the clinical significance of adolescent subthreshold depression and the need for effective interventions, especially for high-risk adolescents.
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The use of statins for the treatment of depression in patients with acute coronary syndrome This study aimed to investigate the effect of statins for the treatment of depression in individuals with acute coronary syndrome (ACS). Methods: We used 1-year follow-up data of a 24-week doubleblind, placebo-controlled trial of escitalopram and a naturalistic prospective observational cohort study. Of 446 participants with comorbid depressive disorders and ACS at baseline, 300 participated in a randomised escitalopram trial and the remaining 146 participated in a naturalistic observational study. The participants in the two studies were approached for a 1-year followup investigation. Treatment response rates, defined as a ≥50% reduction in the Hamilton Depression Rating Scale (HAM-D) and Beck Depression Inventory (BDI) scores, were used as the outcome variables. Results: In the escitalopram trial, both HAM-D and BDI response rates were highest in patients taking escitalopram and statins together and lowest in patients receiving neither medication. Logistic regression analyses revealed that statin use was significantly associated with higher response rates on both the HAM-D and BDI at 1 year whereas no such associations were found for escitalopram. In the naturalistic observational study, the response rates at 1 year did not differ significantly by statin use. Instead, HAM-D response rate was significantly higher in patients taking lipophilic statins than in those who did not. Conclusion: Statins may be effective for the treatment of depression independent of medical status and escitalopram use, and they may potentiate the antidepressant action of serotonergic antidepressants in patients with ACS.
